EUVIMEDEUVIMED entdecken
Scoping ReviewOpen Access · CC BY-NC-ND 4.0

Virus-Specific T-Cell Therapy for Prophylaxis and Treatment of Cytomegalovirus Infections After Transplantation: a Scoping Review

Jollee S T Fung iD, Robert C Wright iD, Dilpreet K Bharaj, Amenah Alghamdi iD, Donna Hesson, Jean-Sébastien Delisle iD, Lorne Schweitzer, Robin K Avery iD, Sara Belga iD

Clinical Infectious Diseases · 06.11.2025 · 81 (4) · e218-e228

DOI: 10.1093/cid/ciaf232 ↗

Kurz gefasst

Scoping Review in der Zeitschrift Clinical Infectious Diseases, online erschienen am 06.05.2025. Verfasst von Jollee S T Fung und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Infectious Diseases, Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada. Hauptthemen laut MEDLINE: Cytomegalovirus Infections, Hematopoietic Stem Cell Transplantation, T-Lymphocytes, Organ Transplantation. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 82 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Cytomegalovirus (CMV) infection is a leading complication following hematopoietic stem cell transplant (HSCT) and solid organ transplant (SOT). Virus-specific T cells (VSTs) have been used for the prophylaxis and treatment of CMV infections. We conducted a scoping review to catalogue and characterize the existing literature.

Methods

Systematic searches were performed in collaboration with an expert librarian. Inclusion criterion was the use of CMV-VST for prophylaxis or treatment in HSCT and SOT patients. Major exclusion criteria were case reports and series with <5 cases. Databases were queried from inception to 31 May 2024. Of the 2587 identified abstracts, full text review was performed on 92 articles, and 67 studies underwent final data extraction.

Results

Most studies were in the HSCT population. The CMV infection rate was 28% (interquartile range [IQR], 14%–44%) when CMV-VSTs were used as prophylaxis. Response rates for non–refractory and/or resistant (R/R) infections and R/R infections in HSCT patients were 98% (IQR, 70%–100%) and 70% (IQR, 56%–88%), respectively. Four studies included SOT patients with R/R infections, demonstrating a response rate of 15%–64%. Variables including donor/recipient serostatus and antiviral use were heterogeneously reported, and various definitions of CMV infection and response were used. CMV-VSTs were well-tolerated with minimal adverse events reported.

Conclusions

CMV-VSTs are more commonly used in HSCT patients with limited data in SOT patients, and differential reporting of key variables precludes extrapolation. A standardized registry should be considered for future studies with additional focus on the optimal dosing, timing, and interaction with concurrent antivirals.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cytomegalovirus InfectionsHematopoietic Stem Cell TransplantationT-LymphocytesOrgan TransplantationHumansCytomegalovirusAntiviral Agents

Stichwörter der Autor:innen

adoptive therapycytomegalovirus infectionorgan transplantationstem cell transplantationvirus-specific T cells

Substanzen

Antiviral Agents

Autor:innen und Institutionen

  • Division of Infectious Diseases, Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
  • Department of Surgery, University of British Columbia, Vancouver, British Columbia, Canada.
  • Childhood Diseases, BC Children's Hospital Research Institute, Vancouver, British Columbia, Canada.
  • Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
  • Division of Infectious Diseases, Department of Internal Medicine, King Abdulaziz University, Jeddah, Saudi Arabia.
  • Welch Medical Library, Johns Hopkins University, Baltimore, Maryland, USA.

ORCID-Profile: Jollee S T Fung, Robert C Wright, Amenah Alghamdi, Jean-Sébastien Delisle, Robin K Avery, Sara Belga

Zitieren

APA

Fung, J. S. T., Wright, R. C., Bharaj, D. K., Alghamdi, A., Hesson, D., Delisle, J. S., Schweitzer, L., Avery, R. K., & Belga, S. (2025). Virus-Specific T-Cell Therapy for Prophylaxis and Treatment of Cytomegalovirus Infections After Transplantation: a Scoping Review. Clinical Infectious Diseases, 81(4), e218-e228. https://doi.org/10.1093/cid/ciaf232

Vancouver

Fung JST, Wright RC, Bharaj DK, Alghamdi A, Hesson D, Delisle JS, et al. Virus-Specific T-Cell Therapy for Prophylaxis and Treatment of Cytomegalovirus Infections After Transplantation: a Scoping Review. Clinical Infectious Diseases. 2025;81(4):e218-e228. doi:10.1093/cid/ciaf232

BibTeX
@article{Fung2025,
  author = {Fung, Jollee S T and Wright, Robert C and Bharaj, Dilpreet K and Alghamdi, Amenah and Hesson, Donna and Delisle, Jean-Sébastien and Schweitzer, Lorne and Avery, Robin K and Belga, Sara},
  title = {Virus-Specific T-Cell Therapy for Prophylaxis and Treatment of Cytomegalovirus Infections After Transplantation: a Scoping Review},
  journal = {Clinical Infectious Diseases},
  year = {2025},
  volume = {81},
  number = {4},
  pages = {e218--e228},
  doi = {10.1093/cid/ciaf232}
}
Kostenlos starten →